Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1982 1
1983 1
1984 1
1985 1
1987 1
1989 2
1990 4
1991 4
1992 4
1993 4
1994 6
1995 2
1997 6
1998 4
1999 3
2000 3
2001 2
2002 5
2003 4
2004 3
2005 1
2006 1
2007 3
2008 2
2009 1
2010 2
2011 2
2013 2
2014 1
2015 1
2016 2
2017 3
2018 6
2019 4
2020 3
2021 5
2022 3
2023 6
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group. Horwitz S, et al. Among authors: lennard a. Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Lancet. 2019. PMID: 30522922 Free PMC article. Clinical Trial.
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial.
Sehn LH, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben J, Lennard A, Lugtenburg PJ, Dimier N, Wassner-Fritsch E, Fingerle-Rowson G, Cheson BD. Sehn LH, et al. Among authors: lennard a. Lancet Oncol. 2016 Aug;17(8):1081-1093. doi: 10.1016/S1470-2045(16)30097-3. Epub 2016 Jun 23. Lancet Oncol. 2016. PMID: 27345636 Clinical Trial.
lnterleukin-1 Receptor Antagonist.
Lennard AC. Lennard AC. Crit Rev Immunol. 2017;37(2-6):531-559. doi: 10.1615/CritRevImmunol.v37.i2-6.160. Crit Rev Immunol. 2017. PMID: 29773033 Review.
Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
Cheson BD, Chua N, Mayer J, Dueck G, Trněný M, Bouabdallah K, Fowler N, Delwail V, Press O, Salles G, Gribben JG, Lennard A, Lugtenburg PJ, Fingerle-Rowson G, Mattiello F, Knapp A, Sehn LH. Cheson BD, et al. Among authors: lennard a. J Clin Oncol. 2018 Aug 1;36(22):2259-2266. doi: 10.1200/JCO.2017.76.3656. Epub 2018 Mar 27. J Clin Oncol. 2018. PMID: 29584548 Clinical Trial.
Interleukin-1 receptor antagonist.
Lennard AC. Lennard AC. Crit Rev Immunol. 1995;15(1):77-105. doi: 10.1615/critrevimmunol.v15.i1.30. Crit Rev Immunol. 1995. PMID: 8519423 Review.
Stem cell transplantation.
Lennard AL, Jackson GH. Lennard AL, et al. BMJ. 2000 Aug 12;321(7258):433-7. doi: 10.1136/bmj.321.7258.433. BMJ. 2000. PMID: 10938056 Free PMC article. Review. No abstract available.
103 results